SCHEMBL924660

SCHEMBL924660

O=C(O)c1cc(-c2ccccn2)c(=O)n(C2CCCC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 8/20 0.44
KDM2A Q9Y2K7 6/20 0.44
KDM4A O75164 5/20 0.44
KDM6B O15054 4/20 0.44
KDM5C P41229 4/20 0.44
KDM4E B2RXH2 3/20 0.44
KDM3A Q9Y4C1 2/20 0.44
BACE1 P56817 1/20 0.44
HSD17B10 Q99714 2/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
KDM5A P29375 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
BRD4 O60885 1/20 0.39
AURKA O14965 1/20 0.38
GSK3B P49841 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL926925 0.86 POLB (0.47) BACE1GAAALDH1A1HPGDBRD4
SCHEMBL924397 0.76 IL4I1 (0.43) KDM4EHSD17B10ALDH1A1BRD4NPC1
SCHEMBL1885321 0.72 CDK4 (0.45) KDM4EHSD17B10GAAALDH1A1BRD4
SCHEMBL926212 0.71 HSD17B10 (0.43) KDM4EHSD17B10GAAALDH1A1HPGD
SCHEMBL924396 0.70 LMNA (0.39) KDM4EHSD17B10GAAALDH1A1HPGD
SCHEMBL1888336 0.70 GRIA1 (0.64)
SCHEMBL924196 0.68 ALDH1A1 (0.54) KDM4EHSD17B10GAAALDH1A1HPGD
SCHEMBL925194 0.68 HSD17B10 (0.40) KDM4EHSD17B10GAAALDH1A1HPGD
SCHEMBL925096 0.68 KDM4E (0.41) KDM4EBACE1HSD17B10GAAALDH1A1
SCHEMBL924275 0.68 GAA (0.40) KDM4EHSD17B10GAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163766-B2 Beta-secretase modulators and methods of use AMGEN INC. (US) 2012-04-24 US disclosed
US-20110118250-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7872009-B2 Beta-Secretase modulators and methods of use AMGEN INC. (US) 2011-01-18 US disclosed
EP-1954693-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE Amgen Inc. (US) 2008-08-13 EP disclosed
US-20070185103-A1 Beta-secretase modulators and methods of use AMGEN INC. 2007-08-09 US disclosed
WO-2007062007-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118250-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP KDM4C 2161/4885KDM2A 1662/4885KDM4A 1900/4885
US-20070185103-A1 Beta-secretase modulators and methods of use BACE1, BACE2, APP KDM4C 2161/4885KDM2A 1662/4885KDM4A 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.